当前位置:首页 - 行情中心 - 艾德生物(300685) - 财务分析 - 现金流量表

艾德生物

(300685)

  

流通市值:71.64亿  总市值:71.74亿
流通股本:3.90亿   总股本:3.90亿

现金流量表

报告期2026-03-312025-12-312025-09-302025-06-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金334,173,795.281,200,445,619.03870,428,221.69556,638,451.47
  收到其他与经营活动有关的现金7,100,761.8352,201,882.3945,712,713.6120,496,468.24
  经营活动现金流入小计341,274,557.111,252,647,501.42916,140,935.3577,134,919.71
  购买商品、接受劳务支付的现金36,768,495.09145,339,557.51108,066,812.4166,363,975.13
  支付给职工以及为职工支付的现金111,671,639.69334,700,879.36255,460,199.33167,322,050.54
  支付的各项税费33,943,038.46150,955,541.85116,092,977.1572,534,139.61
  支付其他与经营活动有关的现金51,603,426.64256,827,463.19161,134,352.94100,331,471.28
  经营活动现金流出小计233,986,599.88887,823,441.91640,754,341.83406,551,636.56
  经营活动产生的现金流量净额107,287,957.23364,824,059.51275,386,593.47170,583,283.15
二、投资活动产生的现金流量:
  收回投资收到的现金152,790,000275,435,885.97259,409,989.45200,000,000
  取得投资收益收到的现金315,337.516,548,988.939,461,421.063,395,060.45
  处置固定资产、无形资产和其他长期资产收回的现金净额-1,843,271.24--
  投资活动现金流入小计153,105,337.5293,828,146.14268,871,410.51203,395,060.45
  购建固定资产、无形资产和其他长期资产支付的现金13,154,595.4570,225,194.7955,714,823.7830,374,747.25
  投资支付的现金318,640,387.8455,500,636.38337,837,164.51204,255,623.45
  投资活动现金流出小计331,794,983.25525,725,831.17393,551,988.29234,630,370.7
  投资活动产生的现金流量净额-178,689,645.75-231,897,685.03-124,680,577.78-31,235,310.25
三、筹资活动产生的现金流量:
  取得借款收到的现金94,000,000100,995,284.1890,000,00065,000,000
  收到其他与筹资活动有关的现金-682,950.42153,559.36129,357.98
  筹资活动现金流入小计94,000,000101,678,234.690,153,559.3665,129,357.98
  偿还债务支付的现金950,00045,749,333.3345,100,00044,400,000
  分配股利、利润或偿付利息支付的现金666,215.99118,947,538.97117,368,747.7193,089,811.38
  支付其他与筹资活动有关的现金84,219,682.1438,684,408.5636,689,965.9935,237,654.13
  筹资活动现金流出小计85,835,898.13203,381,280.86199,158,713.7172,727,465.51
  筹资活动产生的现金流量净额8,164,101.87-101,703,046.26-109,005,154.34-107,598,107.53
四、汇率变动对现金及现金等价物的影响-12,942,140.83-5,142,146.983,602,104.049,345,925.35
五、现金及现金等价物净增加额-76,179,727.4826,081,181.2445,302,965.3941,095,790.72
  加:期初现金及现金等价物余额341,543,017.06315,461,835.82315,461,835.82315,461,835.82
  期末现金及现金等价物余额265,363,289.58341,543,017.06360,764,801.21356,557,626.54
补充资料:
  净利润-361,255,321.05-189,037,382.96
  资产减值准备-31,105,393.02-5,486,930.76
  固定资产和投资性房地产折旧-42,306,936.09-23,507,867.14
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-42,306,936.09-23,507,867.14
  无形资产摊销-8,266,177.06-3,701,408.44
  长期待摊费用摊销-3,554,317.46-2,026,801.97
  处置固定资产、无形资产和其他长期资产的损失--487,729.6-1,759,674.77
  固定资产报废损失-2,842,913.33--43,497.08
  公允价值变动损失--5,727,685.2--3,241,563.21
  财务费用-8,891,184.37--10,255,253.35
  投资损失--8,901,527.36--222,855.74
  递延所得税--2,419,301.65--1,190,183.27
  其中:递延所得税资产减少--2,508,424.37--1,190,183.27
    递延所得税负债增加-89,122.72--
  存货的减少--2,972,577.19--7,552,217.17
  经营性应收项目的减少--105,044,560.22--86,691,916.35
  经营性应付项目的增加-27,690,826.02-52,162,857.41
  现金的期末余额-341,543,017.06-356,557,626.54
  减:现金的期初余额-315,461,835.82-315,461,835.82
  现金及现金等价物的净增加额-26,081,181.24-41,095,790.72
公告日期2026-04-282026-04-162025-10-252025-07-29
审计意见(境内)标准无保留意见
TOP↑